The action of atracurium is terminated by the breakdown of the molecule to various derivatives with insignificant neuromuscular blocking properties ( fig. 1 ). Recovery from neuromuscular blockade is the result of elimination and not redistribution. These interesting properties have made atracurium a fascinating drug to study for the pharmacokineticist. We present data concerning the kinetic profile of atracurium and two of its derivatives in normal patients and in those with renal failure and hepatic dysfunction (Ward and Neill, 1983; Ward et al., 1983; Ward and colleagues, in preparation) .
PATIENTS AND METHODS
Six groups of patients were studied for analysis of atracurium . pharmacokinetic profiles. Three groups were healthy and received different bolus doses of atracurium (0.3 mg kg" 1 ,0.6 mg kg" 1 and 0.75 mg kg" 1 ). One group had chronic renal failure (0.3 mg kg" 1 ), one had acute hepato-renal failure (0.71 mg kg" 1 ) and one group had chronic hepatic disease (0.3 mg kg" 1 ). Each group contained six patients, except the last, which contained five patients.
For analysis of the derivatives of atracurium, three groups were studied: healthy patients (n = 4; 0.3 mg kg" 1 ), chronic renal failure (n = 6; 0.3 mg kg" 1 ) and chronic hepatic disease (n = 5; 0.3 mg kg" 1 ). Each patient received a bolus dose of atracurium i.v. and serial venous blood samples were withdrawn up to 500 min after injection. The plasma from each sample was extracted, acidified and stored at -20 °C within 30 s. Determinations of atracurium and derivative plasma concentrations were performed by high pressure liquid chromatography within 24 h.
In each patient the lungs were ventilated artificially to normocapnia by analysis of end-tidal carbon dioxide concentrations or blood Pco, estimation. Where possible, neuromuscular blockade was allowed to recover spontaneously.
Individual pharmacokinetic profiles were determined from the model parameters derived from each bi-exponential plasma decay for atracurium. The final elimination half-lives and apparent clearances of laudanosine and the monoquaternary alcohol were obtained mathematically from the measured plasma concentrations and the assumed model ( fig. 2 ).
RESULTS
A typical (semi-log) plasma decay curve of atracurium, laudanosine and the monoquaternary alcohol is shown ( fig. 3 ) following a bolus dose of atracurium 0.3 mg kg" 1 to a normal patient. The pharmacokinetic profile of atracurium was not significantly altered by different bolus doses (table I) or by renal or hepatic failure (table II) .
The results of studies with the derivatives are shown in table III. The pharmacokinetic profile of laudanosine was very different from that of atracurium, the terminal half-life being about 200 min. Its elimination was not significantly altered by loss of renal function, but was significantly altered by severe hepatic disease. The peak concentrations of laudanosine were similar in the three groups. The pharmacokinetic profile of the monoquatemary alcohol was more like that of atracurium, with a terminal half-life of about 30 min. Like laudanosine, the elimination was not significantly altered by renal failure, but was extended by severe hepatic disease. Peak concentrations of monoquaternary alcohol also were similar in the three groups.
DISCUSSION
Atracurium was designed to undergo rapid chemical inactivation by Hofmann elimination, fission occurring at the quaternary nitrogen, to give laudanosine and the monoquatemary aery late and ester hydrolysis to give monoquaternary acid and alcohol (S tenlake et al., 1983) . This destruction will occur in the total distribution volume of the drug and will proceed in plasma, even when removed from the circulation. In pharmacokinetic studies, continuing breakdown is minimized by rapid acidification and freezing of each sample and rigorous quality control during determination of plasma concentrations. The pharmacokinetic problem is solved by using an extended twocompartment model ( fig. 2) and by determining the macrokinetic parameters from each plasma decay curve and the area under the curve.
Atracurium has a very short distribution half-life (T\ a approx. 2 min) and a short elimination half-life (TJP approx. 20 min). The short elimination half-life is not significantly altered by renal or hepatic failure, although some increase in distribution volume is seen. Similar results have been obtained from other investigators (Cook et al., 1984; Fahey et al., 1984; Ward and colleagues, in preparation) . Examination of plasma concentrations of the derivatives show that two occurred in significant quantities. The plasma concentrations of each derivative peaked at 2 min after a bolus dose of atracurium, decreased rapidly initially and then more slowly. The monoquaternary alcohol (a product of ester hydrolysis) peaked at 0.5 ug ml" 1 and had a final elimination half-life of 30 min. Smaller concentrations (peak 0.23 (ig ml" 1 ) of laudanosine, a product of Hofmann degradation, were discovered, but its elimination half-life was 220 min. These concentrations and half-lives were not significantly altered by renal failure.
In severe liver disease the initial peak concentrations of both derivatives were similar to those in the other groups, but the apparent clearances and elimination half-lives were significantly altered.
In conclusion, atracurium would appear to be suitable for use in patients with severe renal and hepatic disease, but care would need to be taken during long term i.v. infusions (greater than 24 h) in patients with hepatic dysfunction, as the clearance of laudanosine is reduced and higher than normal steady state blood and other tissue concentrations must be expected.
